Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients.
Sharma, H Thatcher, Nick Baer, J Zaki, A Smith, A McAuliffe, C A Crowther, Derek Owens, S Fox, Brian W
Sharma, H
Thatcher, Nick
Baer, J
Zaki, A
Smith, A
McAuliffe, C A
Crowther, Derek
Owens, S
Fox, Brian W
Citations
Altmetric:
Abstract
The blood and urinary clearances of cis-diammine 1,1-cyclobutane dicarboxylate platinum(II) (CBDCA, JM8) were determined in four patients with malignancy. A 40 muCi iv injection of 191 Pt/193 Pt (3:1)-labelled CBDCA was followed by serial blood and urine sampling to 72 h. The blood clearance was triphasic, mean values for the fast, intermediate, and slow phases being 10.8 min, 2.5 h, and 125 h, respectively. The fraction of activity excreted in the urine within the first 6 h had a mean value of 66.7%, contrasting with 26.4% for cisplatin. There was only a small fraction of CBDCA excreted by the slow phase (1.5%) as against an average of 20% for CHIP and 27% for cisplatin. The early and rapid renal clearance of CBDCA may account for reduced nephrotoxicity.
Description
Date
1983
Publisher
Collections
Keywords
Bronchial Cancer
Type
Article
Citation
Blood clearance of radioactively labelled cis-diammine 1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in cancer patients. 1983, 11 (1):5-7 Cancer Chemother. Pharmacol.